Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma.

Abstract

We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9%) or disease stabilization (47.2%) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p = .034).

• Authors: Judy Ahrar, Sanjay Gupta, Joe Ensor, Kamran Ahrar, David C Madoff, Michael J Wallace, Ravi Murthy, Alda Tam, Patrick Hwu, Agop Y Bedikian
• Journal: Cancer investigation (Cancer Invest) Vol. 29 Issue 1 Pg. 49-55 (Jan 2011) ISSN: 1532-4192 [Electronic] England
• PMID: 21166498 (Publication Type: Journal Article)

Topics

• Chemoembolization, Therapeutic (adverse effects)
• Disease-Free Survival
• Female
• Hepatic Artery
• Humans
• Kaplan-Meier Estimate
• Liver Neoplasms (blood supply, drug therapy, mortality, secondary)
• Male
• Melanoma (blood supply, drug therapy, mortality, secondary)
• Middle Aged
• Proportional Hazards Models
• Retrospective Studies
• Risk Assessment
• Risk Factors
• Skin Neoplasms (mortality, pathology)
• Texas
• Time Factors
• Treatment Outcome